CRELD1

Across TCGA pan-cancer cohorts, CRELD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRELD1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRELD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CRELD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where CRELD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.717	0.971	.001	41	view →
LUAD	DFS	Quartile	II,III,IV	0.750	0.982	.008	11	view →
PDAC	DFS	Median	II,III,IV	0.809	0.655	.020	4	view →
GBM	DFS	Median	All	0.277	0.450	.013	3	view →
HNSC	OS	Median	All	0.899	0.811	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRELD1–CCRCC (OS)

Open the CCRCC breakdown →